178 related articles for article (PubMed ID: 22986230)
1. Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.
Edmonds C; Hagan S; Gallagher-Colombo SM; Busch TM; Cengel KA
Cancer Biol Ther; 2012 Dec; 13(14):1463-70. PubMed ID: 22986230
[TBL] [Abstract][Full Text] [Related]
2. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR
Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer.
Li R; You S; Hu Z; Chen ZG; Sica GL; Khuri FR; Curran WJ; Shin DM; Deng X
PLoS One; 2013; 8(9):e74670. PubMed ID: 24019973
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.
Boehm AL; Sen M; Seethala R; Gooding WE; Freilino M; Wong SM; Wang S; Johnson DE; Grandis JR
Mol Pharmacol; 2008 Jun; 73(6):1632-42. PubMed ID: 18326051
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.
Wu K; Chang Q; Lu Y; Qiu P; Chen B; Thakur C; Sun J; Li L; Kowluru A; Chen F
Oncotarget; 2013 Dec; 4(12):2430-8. PubMed ID: 24280348
[TBL] [Abstract][Full Text] [Related]
7. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
8. Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
Kato T; Jin CS; Lee D; Ujiie H; Fujino K; Hu HP; Wada H; Wu L; Chen J; Weersink RA; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Wilson BC; Zheng G; Yasufuku K
Int J Oncol; 2018 Nov; 53(5):2034-2046. PubMed ID: 30226590
[TBL] [Abstract][Full Text] [Related]
9. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
[TBL] [Abstract][Full Text] [Related]
12. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Chu PL; Shihabuddeen WA; Low KP; Poon DJJ; Ramaswamy B; Liang ZG; Nei WL; Chua KLM; Thong PSP; Soo KC; Yeo ELL; Chua MLK
Photodiagnosis Photodyn Ther; 2019 Sep; 27():367-374. PubMed ID: 31299389
[TBL] [Abstract][Full Text] [Related]
13. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
14. Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity.
Ung N; Putoczki TL; Stylli SS; Ng I; Mariadason JM; Chan TA; Zhu HJ; Luwor RB
Cancer Biol Ther; 2014 May; 15(5):623-32. PubMed ID: 24556630
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
16. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
17. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.
Zhang Q; Bhola NE; Lui VW; Siwak DR; Thomas SM; Gubish CT; Siegfried JM; Mills GB; Shin D; Grandis JR
Mol Cancer Ther; 2007 Apr; 6(4):1414-24. PubMed ID: 17431120
[TBL] [Abstract][Full Text] [Related]
18. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
19. Sustained ERK [corrected] inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy.
Weyergang A; Selbo PK; Berg K
Biochim Biophys Acta; 2013 Mar; 1830(3):2659-70. PubMed ID: 23671927
[TBL] [Abstract][Full Text] [Related]
20. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.
Kluge A; Dabir S; Kern J; Nethery D; Halmos B; Ma P; Dowlati A
Int J Cancer; 2009 Oct; 125(7):1728-34. PubMed ID: 19569236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
